Avenue Therapeutics, Inc. (ATXI)
| Market Cap | 73.02M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -5.15M |
| Shares Out | 16.51M |
| EPS (ttm) | -0.31 |
| PE Ratio | n/a |
| Forward PE | 17.99 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $4.52 |
| Previous Close | $4.23 |
| Change ($) | 0.29 |
| Change (%) | 6.86% |
| Day's Open | 4.29 |
| Day's Range | 4.28 - 4.69 |
| Day's Volume | 195,763 |
| 52-Week Range | 2.85 - 12.34 |
NEW YORK, April 19, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Avenue Therapeutics Inc. ("Avenue" or the "Company") (NASDAQ: ATXI). Such investors are advised...
Avenue Therapeutics (ATXI) has been struggling lately, but the selling pressure may be coming to an end soon
NEW YORK, April 13, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Avenue Therapeutics Inc. ("Avenue" or the "Company") (NASDAQ: ATXI). Such investors are advised...
The FDA Has Not Provided a Decision Regarding the NDA The FDA Has Not Provided a Decision Regarding the NDA
NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today announced that...
NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today announced that...
NEW YORK, Oct. 14, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Avenue Therapeutics, Inc. ("Avenue Therapeutics" or the "Company") (NASDAQ: ATXI). Such investors ...
Avenue Therapeutics' (ATXI) NDA seeking an approval for its pipeline candidate tramadol to treat postoperative pain gets a CRL from the FDA, based on potential safety concerns. Shares down.
Shares of micro-cap biopharma Avenue Therapeutics Inc (NASDAQ: ATXI) are plummeting on above-average volume after a binary event panned out against the company. What Happened: New York-based Avenue said...
Management to Host Conference Call at 8:30 a.m. ET Management to Host Conference Call at 8:30 a.m. ET
NEW YORK, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announc...
Avenue Therapeutics (ATXI) reports a wider-than-expected loss in the second quarter of 2021.
NEW YORK, Aug. 14, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today reported...
Avenue Therapeutics' (ATXI) sole pipeline candidate, tramadol, is under review. With lower clinical activities, operating expenses are likely to have declined during the second quarter.
Avenue Therapeutics, Inc. (ATXI) closed the most recent trading day at $10.30, moving -1.9% from the previous trading session.
Avenue Therapeutics, Inc. (ATXI) closed the most recent trading day at $10.40, moving -1.61% from the previous trading session.
Publication highlights IV tramadol 50 mg demonstrated a statistically significant benefit (p-value < 0.05) over placebo for primary and all key secondary efficacy endpoints Publication highlights IV tra...
Is (ATXI) Outperforming Other Medical Stocks This Year?
Avenue Therapeutics, Inc. (ATXI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
As of late, it has definitely been a great time to be an investor in Avenue Therapeutics
Is (ATXI) Outperforming Other Medical Stocks This Year?
To combat market volatility, it is of utmost importance to create a portfolio of low-beta stocks.
Selecting breakout stocks continue to be one of the most popular methods utilized by active investors.
NEW YORK, June 05, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announce...
Small Drug Industry Prospects Bright Amid Coronavirus Gloom
Avenue (ATXI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Want to try an out-of-the-box approach to earn handsome returns? Tap these stocks with explosive relative price strength.
NEW YORK, May 11, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today reported ...
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 27th
Avenue Therapeutics (ATXI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
A handful of small-cap stocks have skyrocketed defying the coronavirus-induced market mayhem and extreme volatility.
Avenue Therapeutics, Inc. (ATXI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Avenue Therapeutics Update: Shares A Steal Ahead Of Known PDUFA Action Date
NEW YORK, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announce...
Avenue Therapeutics Submits Its NDA; Shares Still Cheap
NEW YORK, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announce...
NEW YORK, Oct. 28, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, announced toda...
NEW YORK, Oct. 18, 2019 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announce...
Shares of Avenue Therapeutics have done virtually nothing over the last four months.
Avenue Therapeutics, Inc. (ATXI) CEO Dr.
Avenue Therapeutics (NASDAQ: ATXI)'s second Phase 3 trial of IV tramadol for the treatment of postoperative pain following abdominoplasty is a success.
About ATXI
Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain. The company was incorporated in 2015 and is based in New York, New York.
| Industry Biotechnology | IPO Date Jun 27, 2017 |
| Stock Exchange NASDAQ | Ticker Symbol ATXI |
Analyst Forecasts
According to 2 analysts, the average rating for ATXI stock is "Buy." The 12-month stock price forecast is 9.00, which is an increase of 99.12% from the latest price.